The new facility is expected to open within 5 years
Muscle and heart disease: including muscle weakness, cardiomyopathy (myocardial hypertrophy or dilation), and arrhythmias.Nervous system effects: may manifest as brain damage, seizures, intellectual disability, ataxia, etc
Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol
Recently, GLP-1 receptor agonists medications (GLP-1s), commonly used for diabetes and weight management, have gained attention for their potential supportive role in endometriosis care
Two major clinical trials are the basis for most of what's known about these medications' weight-management effects: STEP 1 (68-week randomized study, adults without diabetes): semaglutide 2.4 mg produced an average loss of roughly 15% of body weight, versus about 2.4% with placebo, alongside a reduced-calorie diet and increased physical activity